The rate is falling. The death toll is climbing. Both things are true at once, and that contradiction sits at the heart of a new national reckoning with mesothelioma, the rare and brutal cancer that asbestos leaves behind. Pull up the numbers from 1990 and lay them beside 2023 and you would be forgiven for thinking the story was one of slow victory. Age-standardised incidence down by a third. Mortality down by nearly as much. A textbook regulatory success, decades in the making. Except the...